Not all pharma IP law is transferable
This article was originally published in Scrip
Executive Summary
The battle for supremacy between Europe and the US in the fields of pharmaceutical R&D and innovation has pointlessly flared up once again. A recently published survey by international intellectual property specialists Marks & Clerk indicates that the US IP system is viewed as being more favourable to innovation and that President Obama’s recently passed healthcare reforms are proving to be increasingly palatable for big pharma.